Northstrive Biosciences executes research agreement with CRO for EL-32 study

PMGC (ELAB) Holdings announced that its subsidiary, Northstrive Biosciences has executed a research agreement with a preclinical contract research organization specializing in metabolic disorders. This Research Agreement will support a preclinical study carried out by the CRO and designed to evaluate EL-32, a novel engineered probiotic, as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide, focusing on its impact on glycemic control and body composition in diet-induced obese mice. Pursuant to the research agreement, within three months of completion of this study, the CRO will provide results of this study to Northstrive Biosciences and deliver a report to Northstrive Biosciences describing the work envisaged in the Research Agreement. Northstrive Biosciences believes that EL-32 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass. The planned study, titled “Effects of the test agent EL-32 administered either alone or in combination with semaglutide, on glycemic control and body composition in DIO mice,” will use C57BL6/J mice as the experimental model. The study will evaluate body composition and metabolic progress across treatment groups receiving EL-32, semaglutide, or a combination of both.